Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Aug 2017 16:55

RNS Number : 3380O
Dechra Pharmaceuticals PLC
17 August 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

DECHRA PHARMACEUTICALS PLC

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

 

Completion of the court-sanctioned scheme of arrangement and all-share merger under Part 26 of the Companies Act 2006 of Aberdeen Asset Management PLC and Standard Life plc which became effective on 14 August 2017. As a consequence various investment management companies having delegated voting rights across a number of client portfolios have become affiliated entities (per FCA Glossary definition) and threshold limits have been triggered.

 

X

3. Details of person subject to the notification obligationiv

Name

Aggregate of Standard Life Aberdeen plc affiliated investment management entities with delegated voting rights on behalf of multiple managed portfolios

City and country of registered office (if applicable)

Edinburgh, Scotland

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

14/08/2017

6. Date on which issuer notified (DD/MM/YYYY):

16/08/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

8.10

0.00

8.10

93,179,408

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0009633180

0.00

7,550,238

0.00

8.10

SUBTOTAL 8. A

7,550,238

8.10

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Standard Life Investments Limited

4.55

0.00

4.55

Standard Life Wealth Limited

0.67

0.00

0.67

Aberdeen Asset Managers Limited

1.32

0.00

1.32

Aberdeen Asset Investments Limited

1.56

0.00

1.56

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

As a result of the completion of the court-sanctioned scheme of arrangement and all-share merger under Part 26 of the Companies Act 2006 of Aberdeen Asset Management PLC and Standard Life plc which became effective on 14 August 2017, this notification details the assets under management of the new Combined Group ('Standard Life Aberdeen plc') as of the dates noted above.

 

In reference to section 9, the shares detailed are managed by the named discretionary investment management entity within multiple portfolios on behalf of underlying clients, based on investment management agreements whereby the client has delegated the exercise of the voting power to the referenced investment manager.

 

 

Place of completion

Aberdeen, United Kingdom

Date of completion

16/08/2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGMRKNDGNZM
Date   Source Headline
16th Jan 20244:54 pmRNSHolding(s) in Company
16th Jan 20243:29 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20242:43 pmRNSHolding(s) in Company
16th Jan 20241:25 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:15 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:02 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
16th Jan 202412:50 pmRNSForm 8.5 (EPT/RI)-Replacement of Dechra
16th Jan 202412:44 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 202412:04 pmRNSHolding(s) in Company
16th Jan 202410:15 amRNSScheme of Arrangement becomes Effective
16th Jan 202410:11 amRNSForm 8.5 (EPT/NON-RI) - Dechra Pharmaceuticals PLC
16th Jan 202410:11 amRNSForm 8.5 (EPT/RI)
16th Jan 20249:20 amRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20249:04 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
16th Jan 20249:00 amRNSHolding(s) in Company
16th Jan 20248:12 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
16th Jan 20247:39 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
16th Jan 20247:30 amRNSSuspension - Dechra Pharmaceuticals PLC
15th Jan 20244:51 pmRNSDirector/PDMR Shareholding
15th Jan 20243:51 pmRNSHolding(s) in Company
15th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:57 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:46 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
15th Jan 202412:35 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
15th Jan 202412:05 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:51 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:25 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
15th Jan 20249:58 amRNSForm 8.5 (EPT/NON-RI)
15th Jan 20249:58 amRNSForm 8.5 (EPT/RI)
15th Jan 20249:31 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
15th Jan 20249:13 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20247:29 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
12th Jan 20244:02 pmRNSCourt sanction of Scheme of Arrangement
12th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:07 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:42 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:30 pmRNSHolding(s) in Company
12th Jan 20241:38 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
12th Jan 20241:24 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202412:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202410:39 amGNWForm 8.3 - Dechra Pharmaceuticals PLC
12th Jan 202410:39 amRNSForm 8.5 (EPT/RI)
12th Jan 202410:36 amRNSForm 8.5 (EPT/NON-RI)
12th Jan 202410:35 amRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20249:34 amRNSHolding(s) in Company
12th Jan 20249:22 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
12th Jan 20248:09 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.